• Users Online: 157
  • Home
  • Print this page
  • Email this page


 
 Table of Contents  
ARTICLE
Year : 2016  |  Volume : 5  |  Issue : 5  |  Page : 161

Overview of drug-resistant tuberculosis worldwide


Mycobacteriology Research Centre, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Date of Web Publication17-Feb-2017

Correspondence Address:
Parissa Farnia
Mycobacteriology Research Centre, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.1016/j.ijmyco.2016.09.066

Rights and Permissions
  Abstract 


Even in the 21st century, we are losing the battle against eradication of tuberculosis (TB). In 2015, 9.6 million people were estimated to have fallen ill with TB, of which 1.5 million people died. This is the real situation despite the well-structured treatment programs and availability of effective treatment options since the 1950s. The high mortality rate has been associated with other risk factors, such as the HIV epidemic, underlying diseases, and decline of socioeconomic standards. Furthermore, the problem of drug resistance that was recognized in the early days of the chemotherapeutic era raises serious concerns. Although resistance to a single agent is the most common type, resistance to multiple agents is less frequent but of greater concern. The World Health Organization estimated approximately 5% of all new TB cases involved multidrug-resistant (MDR)-TB. The estimation for MDR-TB is 3.3% for new cases, and 20.5% for previously treated cases. Failure to identify and appropriately treat MDR-TB patients has led to more dangerous forms of resistant TB. Based on World Health Organization reports, 5% of global TB cases are now considered to be extensively drug resistant (XDR), defined as MDR with additional resistance to both fluoroquinolones and at least one second-line injectable drug. XDR-TB had been reported by 105 countries by 2015. An estimated 9.7% of people with MDR-TB have XDR-TB. More recently, another dangerous form of TB bacillus was identified, which was named totally drug resistant (TDR-TB) or extremely drug resistant TB. These strains were resistant to all first- and second-line anti-TB drugs. Collectively, it is accepted that 2% of MDR-TB strains turn to be TDR-TB. This number, however, may not reflect the real situation, as many laboratories in endemic TB countries do not have proper facilities and updated protocols to detect the XDR or TDR-TB strains. Nevertheless, existing data emphasize the need for additional control measures, such as new diagnostic methods, better drugs, and more effective vaccines to prevent the spread of these strains around the world.

Keywords: Drug-resistant tuberculosis (DR-TB), Epidemiology, Extensively drug-resistant tuberculosis (XDR-TB), Totally drug-resistant tuberculosis (TDR-TB)


How to cite this article:
Velayati AA, Farnia P, Farahbod AM. Overview of drug-resistant tuberculosis worldwide. Int J Mycobacteriol 2016;5, Suppl S1:161

How to cite this URL:
Velayati AA, Farnia P, Farahbod AM. Overview of drug-resistant tuberculosis worldwide. Int J Mycobacteriol [serial online] 2016 [cited 2019 Nov 20];5, Suppl S1:161. Available from: http://www.ijmyco.org/text.asp?2016/5/5/161/200398




  Conflict of interest Top


The authors has no conflict of interest.





This article has been cited by
1 3D QSAR-based design and liquid phase combinatorial synthesis of 1,2-disubstituted benzimidazole-5-carboxylic acid and 3-substituted-5H-benzimidazo[1,2-d][1,4]benzodiazepin-6(7H)-one derivatives as anti-mycobacterial agents
Nikum D. Sitwala,Vivek K. Vyas,Piyush Gedia,Kinjal Patel,Rania Bouzeyen,Saqib Kidwai,Ramandeep Singh,Manjunath D. Ghate
MedChemComm. 2019;
[Pubmed] | [DOI]
2 High prevalence of multi drug resistant tuberculosis in people living with HIV in Western India
Neil Saldanha,Kiran Runwal,Charulata Ghanekar,Sunil Gaikwad,Shrivallabh Sane,Sanjay Pujari
BMC Infectious Diseases. 2019; 19(1)
[Pubmed] | [DOI]
3 Antitubercular Bis-Substituted Cyclam Derivatives: Structure–Activity Relationships and in Vivo Studies
Malcolm Spain,Joseph K.-H. Wong,Gayathri Nagalingam,James M. Batten,Elinor Hortle,Stefan H. Oehlers,Xiao Fan Jiang,Hasini E. Murage,Jack T. Orford,Patrick Crisologo,James A. Triccas,Peter J. Rutledge,Matthew H. Todd
Journal of Medicinal Chemistry. 2018;
[Pubmed] | [DOI]
4 Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need
Tulshidas S. Patil,Ashwini S. Deshpande,Shirish Deshpande,Pravin Shende
Journal of Drug Targeting. 2018; : 1
[Pubmed] | [DOI]
5 Cytokine and Chemokine Concentrations as Biomarkers of Feline Mycobacteriosis
C. O’Halloran,L. McCulloch,L. Rentoul,J. Alexander,J. C. Hope,D. A. Gunn-Moore
Scientific Reports. 2018; 8(1)
[Pubmed] | [DOI]
6 The systematic modeling studies and free energy calculations of the phenazine compounds as anti-tuberculosis agents
Yueqi Wang,Abbas Khan,Aman Chandra Kaushik,Muhammad Junaid,Xuehong Zhang,Dong-Qing Wei
Journal of Biomolecular Structure and Dynamics. 2018; : 1
[Pubmed] | [DOI]
7 Sericin-chitosan doped maleate gellan gum nanocomposites for effective cell damage in Mycobacterium tuberculosis
Sivaraj Mehnath,Mohamed Ali Ayisha Sithika,Mukherjee Arjama,Mariappan Rajan,Rajendran Amarnath Praphakar,Murugaraj Jeyaraj
International Journal of Biological Macromolecules. 2018;
[Pubmed] | [DOI]
8 Determinant factors of drug resistant tuberculosis in Iran, a case control study
Mahdi Afshari,Mohsen Aarabi,Mohammadreza Parsaee,Asghar Nezammahalleh,Mahmood Moosazadeh
Clinical Epidemiology and Global Health. 2018;
[Pubmed] | [DOI]
9 GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis
Thomas H. King,Crystal A. Shanley,Zhimin Guo,Donald Bellgrau,Timothy Rodell,Synthia Furney,Marcela Henao-Tamayo,Ian M. Orme,David W. Pascual
Clinical and Vaccine Immunology. 2017; 24(12)
[Pubmed] | [DOI]
10 Anti-inflammatory, antimycobacterial and genotoxic evaluation of Doliocarpus dentatus
Raissa Borges Ishikawa,Maicon Matos Leitão,Roberto Mikio Kassuya,Luis Fernando Macorini,Flora Martinez Figueira Moreira,Claudia Andrea Lima Cardoso,Roberta Gomes Coelho,Arnildo Pott,Guilherme Martins Gelfuso,Julio Croda,Rodrigo Juliano Oliveira,Candida Aparecida Leite Kassuya
Journal of Ethnopharmacology. 2017; 204: 18
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Conflict of interest

 Article Access Statistics
    Viewed481    
    Printed29    
    Emailed0    
    PDF Downloaded57    
    Comments [Add]    
    Cited by others 10    

Recommend this journal